3/20/2009

The European Medicines Agency backed the use of Glivec, a cancer drug from Novartis AG, to prevent relapse in patients who underwent surgery for gastrointestinal stromal tumors. The company is seeking to promote wider use of Glivec as a first-line treatment for GIST.

Full Story:
Reuters

Related Summaries